Cell therapy for hard-to-treat autoimmune diseases

Plain-English translation of NCT07236801 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is an early-stage trial testing a new cell therapy called YTS109 for people with autoimmune diseases—like lupus, Sjögren's syndrome, or systemic sclerosis—that have stopped responding to standard treatments. You would receive a single infusion of YTS109 cells, and researchers would carefully monitor you to see whether the treatment is safe and whether it helps reduce your symptoms.

Many people with autoimmune diseases stop responding to available medicines, leaving them with few options. This trial is exploring whether this new cell-based approach might offer hope for patients whose disease is difficult to control.

Do you qualify?

You likely qualify if…

you are between 18 and 65 years old
you have been diagnosed with a relapsing or refractory autoimmune disease (such as lupus, Sjögren's syndrome, systemic sclerosis, or vasculitis) that has not responded adequately to standard treatments
your bone marrow, liver, kidney, and heart function are adequate (tests will confirm this)
you have a platelet count and blood cell counts within acceptable ranges
you are willing to use reliable birth control for 12 months after receiving the treatment

You likely don't qualify if…

you are pregnant, breastfeeding, or unwilling to use contraception for 12 months after treatment
you have severe organ damage or significantly impaired kidney, liver, or heart function
you have active infections or uncontrolled bleeding disorders
you have received certain other cell therapies or biologic treatments very recently without adequate washout time

What participation looks like

If you qualify, you would visit The First Affiliated Hospital of Anhui Medical University for screening tests to confirm your eligibility. On treatment day, you would receive a single infusion of the YTS109 cells into your bloodstream. After that, you would have follow-up visits and blood tests to monitor your safety, any side effects, and whether your symptoms improve over time.

AI-generated summary from trial data · Jun 2, 2026 · Not medical advice

Cell therapy for hard-to-treat autoimmune diseases

What is this trial?

Do you qualify?

What participation looks like

Trial locations